Haloperidol
Brand: Haldol (US/EU) / Serenace (IN) / Halopex (BD)
Antipsychotic
Typical antipsychotic (high-potency D2 antagonist)
Pharmacokinetics
| Half-life | 21 hours |
| Tmax | 4 h |
| Bioavailability | 65 % (approx) |
| Protein Binding | 92 % |
| Volume of Distribution | 22 L/kg (approx) |
| Clearance Route | hepatic |
| Active Metabolites | yes |
| Notes | High risk of EPS; also QT prolongation risk; long-acting decanoate depot IM form available. |
⚠️ Safety & Warnings
Severity: Severe
Adverse Effects:
Extrapyramidal symptoms, akathisia, dystonia, QT prolongation, hyperprolactinemia, NMS
Contraindications:
Parkinson disease, severe CNS depression, prolonged QT
Precautions:
Monitor ECG in cardiac risk; use anticholinergic for acute dystonia if needed; caution in elderly.